Trial Profile

A First-in-Human Phase I Trial to Determine the Safety and the Pharmacokinetic Profile of DSP-0337 in Patients With Advanced Solid Tumors

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 18 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs DSP-0337 (Primary)
Indications Solid tumours
Focus Adverse reactions; First in man
Sponsors Boston Biomedical; Sumitomo Pharma America; Sumitomo Pharma Oncology

Most Recent Events

18 Nov 2020 Status changed from recruiting to discontinued due to alternate development strategy.
20 Jul 2020 Planned End Date changed from 1 Jun 2020 to 1 Aug 2020.
20 Jul 2020 Planned primary completion date changed from 1 May 2020 to 1 Jul 2020.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com